Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14102229 | 0.79 | L3MBTL1 (0.48) | L3MBTL1SRCTDP1MEN1KMT2A | |
| SCHEMBL777196 | 0.75 | SRC (0.48) | L3MBTL1SRCTDP1NPSR1MEN1 | |
| SCHEMBL10635644 | 0.73 | SRC (0.47) | L3MBTL1SRCTDP1MEN1KMT2A | |
| SCHEMBL28590459 | 0.73 | SRC (0.47) | L3MBTL1SRCTDP1NPSR1MEN1 | |
| SCHEMBL22321996 | 0.73 | SRC (0.47) | L3MBTL1SRCTDP1MEN1KMT2A | |
| SCHEMBL4459743 | 0.71 | SRC (0.54) | L3MBTL1SRCTDP1ANPEPLAP3 | |
| SCHEMBL779767 | 0.70 | SRC (0.52) | L3MBTL1SRCTDP1NPSR1MEN1 | |
| SCHEMBL1727266 | 0.70 | SRC (0.52) | L3MBTL1SRCTDP1ANPEPLAP3 | |
| SCHEMBL27586205 | 0.70 | SRC (0.52) | L3MBTL1SRCTDP1ANPEPLAP3 | |
| SCHEMBL9001596 | 0.69 | L3MBTL1 (0.47) | L3MBTL1SRCTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | L3MBTL1 3052/4885SRC 2609/4885TDP1 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.